Key Molecules and Mechanisms in the Progression from Hashimoto’s Thyroiditis to Thyroid Cancer

Molecular Mechanisms Underlying the Transition from Hashimoto’s Thyroiditis to Papillary Thyroid Carcinoma: Insights from Single-Cell and Spatial Transcriptomics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500100156

Enrollment

Unknown

Registered

2025-04-03

Start date

2025-06-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's thyroiditis

Interventions

Severe Hashimoto's thyroid papillary carcinoma group:Na

Non-Hashimoto's thyroid papillary carcinoma group.:Na

Eligibility

Sex/Gender

All

Age

16 Years to 66 Years

Inclusion criteria

Inclusion criteria: 1.PTC patients with a tumor diameter >=2 cm;

Exclusion criteria

Exclusion criteria: 1. Patients who have received chemotherapy or radiotherapy before surgery.

Design outcomes

Primary

Measure	Time frame
Gene expression;	—

Secondary

Measure	Time frame
Thyroid function tests (TFTs), including thyroid peroxidase antibody (TPOAb) and/or thyroglobulin antibody (TgAb);	—

Countries

China

Contacts

Public ContactXiaowei Peng

hunan cancer hospital

pengxiaowei@hnca.org.cn+86 731 88651812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026